{"id":41705,"date":"2024-12-23T10:43:11","date_gmt":"2024-12-23T09:43:11","guid":{"rendered":"https:\/\/www.ablehumanmotion.com\/recapitulacion-2024-logros-claves-de-able\/"},"modified":"2025-01-02T12:14:23","modified_gmt":"2025-01-02T11:14:23","slug":"2024-recap-able-milestones","status":"publish","type":"post","link":"https:\/\/www.ablehumanmotion.com\/en\/2024-recap-able-milestones\/","title":{"rendered":"2024 recap: ABLE’s main achievements"},"content":{"rendered":"\n

2024 has been a pivotal year in our mission to democratize access to robotic rehabilitation. <\/strong>Through our talented team’s daily efforts and our collaborators’ support, we have reached milestones that will lead the way to a more inclusive and technological future.<\/p>\n\n\n\n

Here we proudly and gratefully summarize the highlights of this year.<\/p>\n\n\n\n

\ud83c\udfc62024 key milestones:<\/h2>\n\n\n\n
\n

NEW FACILITIES<\/strong>
A space that allows us to continue growing<\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n
\"\"<\/figure>
\n

OBTAINING CE MARKING<\/strong>
This guarantees the safety and quality of our exoskeleton and allows us to market it in the European Union.<\/a><\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n

FIRST SALES<\/strong>
The first to trust in our technology:
\ud83d\udccdCefine Neurolog\u00eda – A Coru\u00f1a<\/a>
\ud83d\udccdCentro Europeo de Neurociencias (CEN) – Madrid<\/a>
\ud83d\udccdStep by Step – Barcelona<\/a><\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n
\"\"<\/figure>
\n

CLINICAL TRIAL FOR MULTIPLE SCLEROSIS<\/strong>
To validate the ABLE Exoskeleton in people affected by multiple sclerosis (MS) in the Fundaci\u00f3n de Esclerosis M\u00faltiple de Madrid (FEMM)<\/em>.<\/a><\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n

INTERNATIONAL EXPANSION<\/strong>
Distribution agreement with Skyfi in Poland<\/a>.<\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n
\"\"<\/figure>
\n

10 EXOSKELETONS SOLD<\/strong>:
Consolidation of our presence in the national and international market.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n

NEW INDICATIONS<\/strong>
Documentation has been submitted to certify the exoskeleton for the rehabilitation of patients with multiple sclerosis and neuromuscular diseases.<\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n
\"\"<\/figure>
\n

R&D PROJECTS:<\/strong>
\ud83d\udd3aFREEDOM Eurostars<\/a> \u2013 Multiple Sclerosis exoskeleton
\ud83d\udd3aKDT Call 2022<\/a>: \u201cNerveRepack: Intelligent neural system for bidirectional connection with exoprostheses and exoskeletons\u201d
\ud83d\udd3aPublic Private Collaboration<\/a>: Robotic – SNS
\ud83d\udd3aABLE KIDS<\/a>: The first lightweight, quick to fit, frameless and accessible robotic exoskeleton for pediatric neurorehabilitation.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n

CONGRESSES PARTICIPATION:<\/strong>
Mobile World Congress<\/a>\u2013 Barcelona
SERMEF <\/a>\u2013 Madrid
ISCoS<\/a> \u2013 \u00c1mberes, B\u00e9lgica
Congreso de Paraplejia<\/a> \u2013 Toledo
LinkEM<\/a> \u2013 Madrid
RASEN 2024<\/a> \u2013 Valencia
FTP 2024<\/a> \u2013 Barcelona<\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n
\"\"<\/figure>
\n

AWARDS<\/strong>:
\ud83d\udd3aPASS<\/a> Program<\/a>
\ud83d\udd3aAIJEC Awards<\/a><\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n

\ud83d\udcf0 Featured media appearance:<\/h2>\n\n\n\n

We have shared our progress in different media such as:<\/p>\n\n\n\n

\n